5-氯-3H-咪唑并[4,5-b]吡啶 | 52090-89-8

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 5-氯-3H-咪唑并[4,5-b]吡啶
• 中文别名: 5-氯-3H-咪唑[4,5-B]吡啶
• 英文名称: 5-chloro-3H-imidazo[4,5-b]pyridine
• 英文别名: 5-chloro-1H-imidazo[4,5-b]pyridine
• CAS: 52090-89-8
• 化学式: C₆H₄ClN₃
• mdl: MFCD01646134
• 分子量: 153.571
• InChiKey: UWUBPQVLQOHMKF-UHFFFAOYSA-N

物化性质

• 熔点：
  230-232 °C
• 沸点：
  262.4±50.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Chloro-3H-imidazo[4,5-b]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Chloro-3H-imidazo[4,5-b]pyridine
CAS number: 52090-89-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H4ClN3
Molecular weight: 153.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯-3H-咪唑并[4,5-b]吡啶 在 copper(l) iodide 、 trans-N,N-dimethyl-cyclohexane-1,2-diamine 、 sodium hydride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 20.5h， 生成 2-(4-isopropyl-1-oxo-6-(trifluoromethyl)phthalazin-2(1H)-yl)-N-(3-methyl-3H-imidazo[4,5-b]pyridin-5-yl)acetamide
  参考文献：
  名称：

  [EN] COMPOUNDS
  [FR] COMPOSÉS

  摘要：

  本发明涉及用于抑制NLRP3炎症体产生的新化合物，其中所述化合物由公式（I）定义，其中整数R1、R2和R3在描述中定义，且所述化合物可用作药物，例如用于治疗与NLRP3炎症体活性相关的一种疾病或失调。

  公开号：

  WO2021239885A1
• 作为产物：
  描述：

  2-氨基-3-硝基-6-氯吡啶 在 盐酸 、 铁粉 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 生成 5-氯-3H-咪唑并[4,5-b]吡啶
  参考文献：
  名称：

  咪唑并[4,5-b]吡啶的微波辅助C-2直接烯基化：获得具有显着大斯托克斯位移的荧光嘌呤等排体

  摘要：

  我们在此描述了由微波辅助 Pd/Cu 共催化促进的有价值的 3H-咪唑并 [4,5-b] 吡啶的第一次 C-2 直接烯基化。该反应快速且与咪唑并[4,5-b]吡啶环或苯乙烯基溴上的各种官能团相容，从而以中等至良好的产率分离出23种化合物。该方法的相关性通过其在合成新的交叉共轭推拉 2-乙烯基和 2-炔基咪唑并[4,5-b] 吡啶中的应用而得到证明，其特征在于具有令人满意的荧光量子产率和显着的溶剂化荧光变色特性。

  DOI：

  10.1002/ejoc.201600166

文献信息

• Direct Alkynylation of 3<i>H</i>-Imidazo[4,5-<i>b</i>]pyridines Using <i>gem</i>-Dibromoalkenes as Alkynes Source
  作者：Jessy Aziz、Tom Baladi、Sandrine Piguel

  DOI：10.1021/acs.joc.6b00406

  日期：2016.5.20

  C2 direct alkynylation of 3H-imidazo[4,5-b]pyridine derivatives is explored for the first time. Stable and readily available 1,1-dibromo-1-alkenes, electrophilic alkyne precursors, are used as coupling partners. The simple reaction conditions include an inexpensive copper catalyst (CuBr·SMe2 or Cu(OAc)2), a phosphine ligand (DPEphos) and a base (LiOtBu) in 1,4-dioxane at 120 °C. This C–H alkynylation

  首次探索了3 H-咪唑并[4,5- b ]吡啶衍生物的C2直接炔基化。稳定且易于获得的1,1-二溴-1-烯烃（亲电炔前体）用作偶联伙伴。简单的反应条件包括：廉价的铜催化剂（CuBr·SMe 2或Cu（OAc）2），膦配体（DPEphos）和1,4-二恶烷中的碱（LiO t Bu）在120°C的条件下。该C-H炔基化方法显露是与各种上两个耦合伙伴取代的兼容：杂芳烃和宝石-dibromOAlkenes。该协议可以直接合成各种2-炔基-3 H-咪唑并[4,5- b]吡啶，一种在药物设计中有价值的支架。
• [EN] BICYCLIC HETEROARYL DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLE BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE/PHOSPHODIESTÉRASE 1
  申请人：RIBOSCIENCE LLC

  公开号：WO2020210649A1

  公开（公告）日：2020-10-15

  The present disclosure provides certain bicyclic heteroaryl compounds that inhibit ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) enzymatic activity and are therefore useful for the treatment of diseases and conditions modulated at least in part by ENPP1. In some embodiments, the bicyclic heteroaryl compounds includes those of Formula (I). Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本公开提供了一些抑制细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）酶活性的双环杂环芳基化合物，因此对于治疗至少部分受ENPP1调节的疾病和病况是有用的。在某些实施例中，双环杂环芳基化合物包括式（I）中的化合物。本文还提供了含有这类化合物的药物组合物以及制备这类化合物的方法。
• [EN] METABOTROPIC GLUTAMATE RECEPTOR MODULATORS<br/>[FR] MODULATEURS DES RÉCEPTEURS MÉTABOTROPES AU GLUTAMATE
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2012052451A1

  公开（公告）日：2012-04-26

  The invention relates to heterocyclic derivatives of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders wherein Y, W, R1, R2 and R3 are as defined in claim 1.

  该发明涉及公式（I）的杂环衍生物及其药学上可接受的盐。该发明还涉及制备这类化合物的方法。该发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病是有用的，其中Y、W、R1、R2和R3如权利要求1中所定义。
• [EN] PURINE DERIVATIVES AS CD73 INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PURINE EN TANT QU'INHIBITEURS DE CD73 POUR LE TRAITEMENT DU CANCER
  申请人：VITAE PHARMACEUTICALS INC

  公开号：WO2015164573A1

  公开（公告）日：2015-10-29

  Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.

  提供的是新颖化合物、其药学上可接受的盐以及其药物组合物，这些化合物是CD73的抑制剂，并可用于癌症治疗。
• [EN] BICYCLIC HETEROARYL DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLES BICYCLIQUES EN TANT QU'INHIBITEURS DE KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2013078254A1

  公开（公告）日：2013-05-30

  The present invention provides compounds, including resolved enantiomers, resolved diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula 1: wherein Het, X, R1 and R2 are as defined herein.

  本发明提供了化合物，包括已分离的对映体、已分离的异构体、溶剂合物和其药学上可接受的盐，其化学式如下：其中Het、X、R1和R2的定义如本文所述。